Randomized, Open-Label, Parallel Group Study To Investigate The Safety And Tolerability Of Multiple Dose Lersivirine (Proposed Phase 3 Formulation) For 21 Days In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 May 2011
At a glance
- Drugs Lersivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 16 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2011 Planned End Date changed from 1 Apr 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 20 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 Apr 2011, as reported by ClinicalTrials.gov.